Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.65
EXAC's Cash-to-Debt is ranked lower than
70% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. EXAC: 0.65 )
Ranked among companies with meaningful Cash-to-Debt only.
EXAC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.19 Max: 1.08
Current: 0.65
0.03
1.08
Equity-to-Asset 0.80
EXAC's Equity-to-Asset is ranked higher than
82% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. EXAC: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
EXAC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59  Med: 0.74 Max: 0.83
Current: 0.8
0.59
0.83
Interest Coverage 7.53
EXAC's Interest Coverage is ranked lower than
80% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. EXAC: 7.53 )
Ranked among companies with meaningful Interest Coverage only.
EXAC' s Interest Coverage Range Over the Past 10 Years
Min: 7.53  Med: 16.85 Max: 28.71
Current: 7.53
7.53
28.71
Piotroski F-Score: 4
Altman Z-Score: 6.00
Beneish M-Score: -3.00
WACC vs ROIC
7.05%
0.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 2.96
EXAC's Operating Margin % is ranked higher than
51% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. EXAC: 2.96 )
Ranked among companies with meaningful Operating Margin % only.
EXAC' s Operating Margin % Range Over the Past 10 Years
Min: 2.96  Med: 9.59 Max: 12.05
Current: 2.96
2.96
12.05
Net Margin % 0.06
EXAC's Net Margin % is ranked lower than
55% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. EXAC: 0.06 )
Ranked among companies with meaningful Net Margin % only.
EXAC' s Net Margin % Range Over the Past 10 Years
Min: 0.06  Med: 5.9 Max: 7.19
Current: 0.06
0.06
7.19
ROE % 0.07
EXAC's ROE % is ranked lower than
56% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. EXAC: 0.07 )
Ranked among companies with meaningful ROE % only.
EXAC' s ROE % Range Over the Past 10 Years
Min: 0.07  Med: 7.68 Max: 10.86
Current: 0.07
0.07
10.86
ROA % 0.06
EXAC's ROA % is ranked lower than
51% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. EXAC: 0.06 )
Ranked among companies with meaningful ROA % only.
EXAC' s ROA % Range Over the Past 10 Years
Min: 0.06  Med: 5.43 Max: 7.81
Current: 0.06
0.06
7.81
ROC (Joel Greenblatt) % 3.82
EXAC's ROC (Joel Greenblatt) % is ranked lower than
51% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. EXAC: 3.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EXAC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.82  Med: 12.67 Max: 17.82
Current: 3.82
3.82
17.82
3-Year Revenue Growth Rate 1.20
EXAC's 3-Year Revenue Growth Rate is ranked lower than
63% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. EXAC: 1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EXAC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 13.7 Max: 30.5
Current: 1.2
-1.1
30.5
3-Year EBITDA Growth Rate -14.50
EXAC's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. EXAC: -14.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EXAC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.5  Med: 11 Max: 38
Current: -14.5
-14.5
38
3-Year EPS without NRI Growth Rate -79.30
EXAC's 3-Year EPS without NRI Growth Rate is ranked lower than
97% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EXAC: -79.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EXAC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -79.3  Med: 11.9 Max: 34.6
Current: -79.3
-79.3
34.6
GuruFocus has detected 3 Warning Signs with Exactech Inc $EXAC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EXAC's 10-Y Financials

Financials (Next Earnings Date: 2017-05-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EXAC Guru Trades in Q1 2016

Jim Simons 90,800 sh (+14.36%)
Mario Gabelli 666,009 sh (+2.58%)
Chuck Royce 409,474 sh (-31.36%)
» More
Q2 2016

EXAC Guru Trades in Q2 2016

Jeremy Grantham 9,121 sh (New)
Mario Gabelli 665,609 sh (-0.06%)
Jim Simons 90,100 sh (-0.77%)
Chuck Royce 322,320 sh (-21.28%)
» More
Q3 2016

EXAC Guru Trades in Q3 2016

Jim Simons 98,600 sh (+9.43%)
Jeremy Grantham 9,121 sh (unchged)
Mario Gabelli 658,109 sh (-1.13%)
Chuck Royce 226,428 sh (-29.75%)
» More
Q4 2016

EXAC Guru Trades in Q4 2016

Jim Simons 105,700 sh (+7.20%)
Chuck Royce 240,128 sh (+6.05%)
Mario Gabelli 654,635 sh (-0.53%)
Jeremy Grantham 8,821 sh (-3.29%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NAS:ELOS, NAS:ARAY, NYSE:IVC, NAS:AXGN, NAS:TCMD, NAS:VRAY, NAS:XENT, NAS:CUTR, OTCPK:NMRD, AMEX:CVRS, NAS:RTIX, OTCPK:IPDQF, NYSE:CRY, OTCPK:MZRTF, NAS:OBLN, NAS:PAVM, NAS:IRIX, OTCPK:SBMAF, NAS:ACRX, NAS:GNMK » details
Exactech Inc develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.

Exactech Inc was founded by an orthopaedic surgeon in November 1985, and is incorporated under the laws of the State of Florida. The Company develops, manufactures, markets, distributes and sella orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. Its U.S. sales and distribution activities are conducted by its wholly owned subsidiary Exactech U.S., Inc. The Companys international development, sales and distribution activities are conducted by its wholly owned subsidiary Exactech International Operations, AG based in Bern, Switzerland. The Company manufactures some components of its knee, extremity, and hip joint replacement systems at its facility in Gainesville, Florida, utilizing modern, automated computer aided manufacturing equipment. Its cellular based manufacturing processes, which are organized in groups, or cells, are dedicated to specific product lines to minimize change-over and increase efficiency. To supplement its manufacturing of components, the company has formed strategic alliances with suppliers and business partners to externally manufacture some components. Additionally, the company acquires and distribute other products and services through exclusive agreements, such as its agreement with Tecres S.p.A, (Tecres) and Blue Ortho, SAS (Blue Ortho), and non-exclusive agreements, such as with RTI Surgical, Inc., (RTI), and Biomatlante SARL, (Biomatlante). The company markets its orthopaedic implant products in the United States through Exactech U.S., Inc. that operates through a network of independent sales agencies and direct sales representatives. The company offers its products in all fifty states, Puerto Rico, and the District of Columbia. The Companys competitors in the orthopaedic market are DePuy, Inc., a division of Johnson and Johnson, Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., Stryker Corporation, Smith and Nephew plc, and Biomet, Inc. The Companys operations are subject to numerous and increasingly stringent federal, state and local environmental laws and regulations in the United States and other countries in which operates.

Guru Investment Theses on Exactech Inc

Meridian Funds Comments on Exact Sciences Corp - Mar 08, 2016

Exact Sciences Corp. (NASDAQ:EXAC) declined after an independent panel of health care experts excluded the company’s colon cancer-screening test from a list of recommended tests in the U.S. Instead, the panel defined the product as “alternative testing that may be useful in select clinical circumstances.” Marketed as Cologuard, the product is a non-invasive, FDA-approved colorectal cancer-screening test covered by Medicare. It has proven effective at detecting early-stage colon cancer as well as precancerous lesions. When detected early, colon cancer is highly curable. However, Cologuard’s exclusion from the panel’s list of recommended tests may make it more difficult to win favorable reimbursement from private insurers. We consequently liquidated our position in Exact Sciences and used proceeds from the sale to invest in other, more attractive investment opportunities.





From the Meridian Equity Income Fund fourth quarter commentary.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
Forward PE Ratio 20.75
EXAC's Forward PE Ratio is ranked higher than
67% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.98 vs. EXAC: 20.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.62
EXAC's PB Ratio is ranked higher than
76% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. EXAC: 1.62 )
Ranked among companies with meaningful PB Ratio only.
EXAC' s PB Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.55 Max: 3.48
Current: 1.62
1.06
3.48
PS Ratio 1.49
EXAC's PS Ratio is ranked higher than
72% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. EXAC: 1.49 )
Ranked among companies with meaningful PS Ratio only.
EXAC' s PS Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.26 Max: 2.58
Current: 1.49
0.85
2.58
Price-to-Operating-Cash-Flow 12.75
EXAC's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. EXAC: 12.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EXAC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.92  Med: 11.13 Max: 49.48
Current: 12.75
5.92
49.48
EV-to-EBIT 50.26
EXAC's EV-to-EBIT is ranked lower than
81% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 22.27 vs. EXAC: 50.26 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAC' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 14.5 Max: 53.2
Current: 50.26
9.2
53.2
EV-to-EBITDA 14.46
EXAC's EV-to-EBITDA is ranked higher than
57% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. EXAC: 14.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 8.5 Max: 15.3
Current: 14.46
6
15.3
Shiller PE Ratio 31.33
EXAC's Shiller PE Ratio is ranked higher than
78% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 53.11 vs. EXAC: 31.33 )
Ranked among companies with meaningful Shiller PE Ratio only.
EXAC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.72  Med: 25.32 Max: 51.8
Current: 31.33
17.72
51.8
Current Ratio 4.32
EXAC's Current Ratio is ranked higher than
78% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. EXAC: 4.32 )
Ranked among companies with meaningful Current Ratio only.
EXAC' s Current Ratio Range Over the Past 10 Years
Min: 3.57  Med: 4.54 Max: 8.23
Current: 4.32
3.57
8.23
Quick Ratio 2.35
EXAC's Quick Ratio is ranked higher than
63% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. EXAC: 2.35 )
Ranked among companies with meaningful Quick Ratio only.
EXAC' s Quick Ratio Range Over the Past 10 Years
Min: 1.23  Med: 2.04 Max: 3.84
Current: 2.35
1.23
3.84
Days Inventory 329.06
EXAC's Days Inventory is ranked lower than
89% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. EXAC: 329.06 )
Ranked among companies with meaningful Days Inventory only.
EXAC' s Days Inventory Range Over the Past 10 Years
Min: 310.86  Med: 346.51 Max: 357.51
Current: 329.06
310.86
357.51
Days Sales Outstanding 75.18
EXAC's Days Sales Outstanding is ranked lower than
57% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. EXAC: 75.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.9  Med: 75.72 Max: 91
Current: 75.18
67.9
91
Days Payable 79.89
EXAC's Days Payable is ranked higher than
64% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. EXAC: 79.89 )
Ranked among companies with meaningful Days Payable only.
EXAC' s Days Payable Range Over the Past 10 Years
Min: 52.26  Med: 78.53 Max: 90.48
Current: 79.89
52.26
90.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
EXAC's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. EXAC: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.9  Med: -1.5 Max: -1.2
Current: -1.5
-3.9
-1.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 4.57
EXAC's Price-to-Net-Current-Asset-Value is ranked higher than
67% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. EXAC: 4.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EXAC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.87  Med: 4.55 Max: 18.45
Current: 4.57
1.87
18.45
Price-to-Tangible-Book 1.81
EXAC's Price-to-Tangible-Book is ranked higher than
81% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 4.36 vs. EXAC: 1.81 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXAC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 2.1 Max: 3.73
Current: 1.81
1.26
3.73
Price-to-Intrinsic-Value-Projected-FCF 1.71
EXAC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. EXAC: 1.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EXAC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.86  Med: 3.09 Max: 18.34
Current: 1.71
0.86
18.34
Price-to-Median-PS-Value 1.18
EXAC's Price-to-Median-PS-Value is ranked lower than
56% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. EXAC: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXAC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.79  Med: 1.18 Max: 2.14
Current: 1.18
0.79
2.14
Price-to-Graham-Number 14.65
EXAC's Price-to-Graham-Number is ranked lower than
95% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. EXAC: 14.65 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EXAC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.95  Med: 1.48 Max: 14.92
Current: 14.65
0.95
14.92
Earnings Yield (Greenblatt) % 1.99
EXAC's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. EXAC: 1.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXAC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 6.9 Max: 10.8
Current: 1.99
1.9
10.8
Forward Rate of Return (Yacktman) % 2.50
EXAC's Forward Rate of Return (Yacktman) % is ranked lower than
70% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.85 vs. EXAC: 2.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EXAC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.4  Med: 8.8 Max: 14
Current: 2.5
2.4
14

More Statistics

Revenue (TTM) (Mil) $257.6
Beta0.65
Short Percentage of Float0.76%
52-Week Range $18.14 - 29.00
Shares Outstanding (Mil)14.30

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 268 286 306
EPS ($) 1.29 1.44 1.60
EPS without NRI ($) 1.29 1.44 1.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.20%
Dividends per Share ($)
» More Articles for EXAC

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Exact Sciences Corp Mar 08 2016 
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 28 2013 
Mario Gabelli Ups His Holdings in EXAC, TWIN and LAYN Jun 28 2013 
Exactech Inc. Reports Operating Results (10-K) Mar 16 2011 
Exactech Inc. Reports Operating Results (10-Q) Nov 09 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Exactech Inc. Reports Operating Results (10-Q) May 05 2010 
Exactech Inc. (EXAC) CFO and Treasurer Joel C Phillips sells 2,497 Shares May 04 2010 
Exactech Inc. (EXAC) CEO and Chairman, 10% Owner R William Petty sells 20,000 Shares Dec 11 2009 
Exactech Inc. Reports Operating Results (10-Q) Nov 05 2009 

More From Other Websites
Exactech, Inc. :EXAC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Exactech, Inc. breached its 50 day moving average in a Bullish Manner : EXAC-US : March 17, 2017 Mar 17 2017
Exactech, Inc. :EXAC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Exactech Announces Full Launch of Three Revision Systems and Expansion of Advanced Surgical... Mar 14 2017
Exactech Announces Investor Presentation at 12th Annual CanaccordGenuity Musculoskeletal Conference Mar 13 2017
EXACTECH INC Financials Mar 11 2017
EXACTECH INC Files SEC form 10-K, Annual Report Mar 08 2017
Exactech Posts Q4 Loss of 82 Cents a Share Feb 22 2017
Edited Transcript of EXAC earnings conference call or presentation 21-Feb-17 3:00pm GMT Feb 21 2017
Exactech reports 4Q loss Feb 21 2017
Exactech reports 4Q loss Feb 21 2017
EXACTECH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 21 2017
Exactech 2016 Revenue Up 7% to $257.6 Million, Q4’16 Revenue Increased 6% to $66.2 Million Feb 21 2017
Q4 2016 Exactech Inc Earnings Release - Before Market Open Feb 21 2017
These drug and medical device companies made the most payments to N.Y.C. hospitals Feb 14 2017
Exactech Schedules Fourth Quarter and Year-End 2016 Earnings Release and Conference Call Feb 13 2017
EXACTECH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 01 2017
Exactech Announces Divestiture of Spine Assets and Restructuring Charges Jan 31 2017
ETFs with exposure to Exactech, Inc. : January 20, 2017 Jan 20 2017
Exactech, Inc. – Value Analysis (NASDAQ:EXAC) : January 19, 2017 Jan 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)